# Seqirus clinical trials: 53 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 53 trials with Seqirus as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Seqirus: 53 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/seqirus

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 53
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 53, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 18, 2023 | NCT06087640 | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted... | Seqirus | Phase 3 | Completed | Influenza, Human | 38,769 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06087640) |
| September 8, 2023 | NCT06028347 | Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy Adults | Seqirus | Phase 1 | Completed | Influenza, Human | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06028347) |
| August 29, 2023 | NCT06015282 | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | Seqirus | Phase 3 | Completed | Influenza, Human | 7,741 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06015282) |
| May 25, 2023 | NCT05875961 | Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults | Seqirus | Phase 1 | Completed | Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05875961) |
| May 25, 2023 | NCT05874713 | Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in... | Seqirus | Phase 2 | Completed | Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05874713) |
| August 15, 2022 | NCT05501561 | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age | Seqirus | Phase 2 | Completed | Influenza, Human | 1,056 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05501561) |
| June 16, 2022 | NCT05422326 | A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1... | Seqirus | Phase 2 | Completed | Influenza, Human, Influenza in Birds, Respiratory Tract Infections, Infections, Orthomyxoviridae Infections, RNA Virus... | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05422326) |
| September 14, 2021 | NCT05044195 | A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed... | Seqirus | Phase 3 | Completed | Influenza, Human | 2,044 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05044195) |
| March 19, 2021 | NCT04806529 | An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults... | Seqirus | Phase 2/3 | Withdrawn | Influenza | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04806529) |
| March 4, 2021 | NCT04782323 | Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | Seqirus | Phase 2 | Completed | Influenza | 839 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04782323) |
| December 17, 2020 | NCT04669691 | A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine | Seqirus | Phase 2 | Completed | Influenza, Human | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04669691) |
| October 6, 2020 | NCT04576702 | Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults | Seqirus | Phase 2 | Completed | Influenza, Human | 471 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04576702) |
| August 30, 2019 | NCT04074928 | Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects | Seqirus | Phase 3 | Completed | Influenza, Human, Virus Diseases | 2,414 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04074928) |
| May 1, 2019 | NCT03932682 | Efficacy Study With QIVc in Pediatric Subjects | Seqirus | Phase 3 | Completed | Influenza, Human | 5,723 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03932682) |
| February 22, 2018 | NCT03442582 | Afluria Pregnancy Registry | Seqirus | Observational | Completed | Influenza, Human, Pregnancy, Birth Defect | 490 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03442582) |
| February 19, 2018 | NCT03438487 | Flucelvax (TIVc or QIVc) Pregnancy Registry | Seqirus | Observational | Completed | Influenza, Human, Pregnancy, Birth Defect | 692 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03438487) |
| October 19, 2017 | NCT03314662 | Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults | Seqirus | Phase 3 | Completed | Influenza, Human | 1,778 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03314662) |
| May 24, 2017 | NCT03165617 | Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to \<18 Years of Age | Seqirus | Phase 3 | Completed | Influenza, Human | 4,514 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03165617) |
| September 26, 2016 | NCT02914275 | A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months... | Seqirus | Phase 3 | Completed | Influenza, Human | 2,250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02914275) |
| July 20, 2016 | NCT02839330 | A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects... | Seqirus | Phase 3 | Completed | Avian Influenza | 3,196 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02839330) |
| October 27, 2015 | NCT02587221 | Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to... | Seqirus | Phase 3 | Completed | Influenza | 6,790 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02587221) |
| October 22, 2015 | NCT02583256 | Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously... | Seqirus | Phase 3 | Completed | Influenza | 1,601 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02583256) |
| September 10, 2015 | NCT02545543 | A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17... | Seqirus | Phase 3 | Completed | Influenza, Human | 2,278 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02545543) |
| October 7, 2014 | NCT02258178 | Flucelvax Pregnancy Registry | Seqirus | Observational | Withdrawn | Pregnant Women, Influenza | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02258178) |
| October 2, 2014 | NCT02255409 | Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children... | Seqirus | Phase 3 | Completed | Influenza | 607 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02255409) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 6 |
| Phase 1/2 | 1 |
| Phase 2 | 14 |
| Phase 2/3 | 1 |
| Phase 3 | 19 |
| Phase 4 | 9 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 51 |
| Withdrawn | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Influenza, Human | 51 |
| Virus Diseases | 6 |
| Influenza in Birds | 4 |
| Infections | 3 |
| Respiratory Tract Infections | 3 |
| Congenital Abnormalities | 2 |
| Orthomyxoviridae Infections | 1 |
| RNA Virus Infections | 1 |
| Respiratory Tract Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Child care centers in the United States](https://specstream.ai/data/businesses/child-care-centers/united-states)
- [Car manufacturers in the United States](https://specstream.ai/data/businesses/car-manufacturers/united-states)
- [Building supply stores in the United States](https://specstream.ai/data/businesses/building-supply-stores/united-states)
- [Biotechnology companies in the United States](https://specstream.ai/data/businesses/biotechnology-companies/united-states)
- [Banks in the United States](https://specstream.ai/data/businesses/banks/united-states)
- [B2B outdoor advertising companies in the United States](https://specstream.ai/data/businesses/b2b-outdoor-advertising-companies/united-states)
